Home > Inhibitors & Agonists
Cat. No. Product name CAS No.
DCC2793 Jak-in-3

Novel potent JAK1/3 inhibitor, targeting JAK3 and JAK1 with IC 50 at 3nM and 5nM, respectively

1400876-94-9
DCC2794 Jami1001a

Novel positive allosteric modulator of AMPA receptor

1001019-46-0
DCC2795 Jamunone M

Novel anti-triple-negative breast cancer (anti-TNBC) agent with a high selectivity against BC cells over normal human cells, downregulating phosphatidylinositide 3-kinase (PI3K)/Akt pathway by suppressing protein-tyrosine phosphatase 1B (PTP1B) expression

DCC2796 Janelia Fluor 526, Se

Novel fluorogenic yellow fluorescent dye for use in self-labeling tag systems

DCC2797 Jar1.39

Novel mitophagy inducer with therapeutic potential for Parkinson's disease, acting as light chain 3 (LC3) interactors, similar to cardiolipin or ceramide, triggering mitophagy via Pink1/Parkin

DCC2798 jarid1b Demethylase Inhibitor

Novel Inhibitor of Jumonji AT-Rich Interactive Domain 1B (JARID1B) Histone Demethylase

351190-46-0
DCC2799 Jasminine

Natural naphthyridine alkaloid

19634-30-1
DCC2800 Jasplakinolide

Potent inhibitor of the proliferation of PC3 prostate carcinoma cells

102396-24-7
DCC2801 Jbir-22

Natural Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3

DCC2802 Jbir-59

Natural radical scavenger, inhibiting L-glutamate toxicity in neuronal hybridoma N18-RE-105 cells

DCC2803 Jbp485

Inhibitor of renal transporters OAT1 and OAT3; Antihepatitis agent as a substrate for intestinal PEPT1

211868-63-2
DCC2804 Jbp923

Natural anti-inflammatory agent, showing potential for the treatment of inflammatory bowel disease (IBD)

DCC2805 Jbsnf-000567

Metabolite of JBSNF-000088

DCC2806 Jc1-40

Novel RORα activator, diminishing diethylnitrosamine-induced acute liver injury and repressing transcriptional expression of APPs such as CXCL1 and LCN2 in mice

DCC2807 Jcp-170

Novel dose-dependent inhibitor of ABHD6

120218-98-6
DCC2808 jcp174-alk

JCP174 analog used for affinity purification of labeled targets

1357347-91-1
DCC2809 jcp174-ia

Negative control of JCP174

1034705-86-6
DCC2810 Jcp-265

Novel dose-dependent inhibitor of ABHD6

140652-99-9
DCC2811 Jcp405

Covalent dual inhibitor of DPAP1 and DPAP3

DCC2812 Jcp410

Covalent dual inhibitor of DPAP1 and DPAP3

DCC2813 Jcp474

Novel potent inhibitor of Mpro

DCC2814 Jcp678

Novel irriversable serine hydrolases inhibitor

82422-62-6
DCC2815 jd-5006

Peripheral Selective CB1 Receptor Antagonist

1404117-64-1
DCC2816 Jesridonin

Novel apoptosis inducer, significantly inhibiting tumor growth in the xenograft model

2074768-37-7
DCC2817 Jfd00950

Novel human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1

882278-66-2
DCC2818 Jg2-38

Novel inhibitor of the heat shock protein 70 (Hsp70) with anti-proliferative activity in breast and prostate cancer cells

DCC2819 Jh-i-17

Novel type I Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4

DCC2820 Jh-i-25

Novel Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4

1042673-20-0
DCC2821 Jk-136

Novel Ras homologous A (RHOA) inhibitor, potently inhibiting cell viability and migration/invasion of gastric cancer (GC) cell lines, and mouse xenografts, diversely expressing RHOA, binding affinity for RHOA was >140-fold greater than Rhosin, a nonclinic

DCC2822 Jk-31 (vegfr2/cdk1 Inhibitor)

Novel specific dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1), targeting cell cycle progression and angiogenesis

DCC2823 Jlj-334

Potent non-nucleoside inhibitor of HIV-1 reverse transcriptase (NNRTIs)

1351862-50-4
DCC2824 Jmv2951

Novel potent GHS-R1a agonist (EC50 (Ca ): 1.6 nM), significantly stimulating GH secretion

DCC2825 Jmv3168

Novel ghrelin receptor (GHS-R1a) antagonist [IC 50 (affinity): 5 nM IC 50 (Ca ): 60 nM]

DCC2826 Jmv4484

Novel partial inverse agonist of GHS-R1a (K i = 3 nM, EC 50 = 70 nM, Emax = −37%)

DCC2827 Jmx0207

Novel inhibitor of viral protease function, suppressing Zika virus Infection both In vitro and In vivo

33580-97-1
DCC2828 Jmx0254

Novel Potent NS4B Inhibitor for the Treatment of Dengue Virus Infection

DCC2829 Jmx0510-2

Novel Potent Human Adenovirus Inhibitor, showing improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreasing cytotoxicity (CC50 = 156.8 μM), and lowering in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosam

DCC2830 Jnj-1013

Novel potent and selective IRAK1 degrader, effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells

DCC2831 Jnj-10311795

Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase

518062-14-1
DCC2832 Jnj-17029259

Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor

314267-57-7
DCC2833 Jnj-17148066

Estrogen receptor ESR1 agonist

554431-74-2
DCC2834 Jnj-1930942

Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor

929562-28-7
DCC2835 Jnj-20788560

Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent

825649-28-3
DCC2836 Jnj-26076713

Novel EthR inhibitor, boosting antituberculous activity of ethionamide

669076-03-3
DCC2837 Jnj-28330835

Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats

888072-47-7
DCC2838 Jnj-28583867

Histamine H3 receptor antagonist and serotonin reuptake inhibitor

892407-39-5
DCC2839 Jnj-40068782

Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors

950196-50-6
DCC2840 Jnj-40255293

Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease

1147271-25-7
DCC2841 Jnj-40264796

Negative control for JNJ-40068782

DCC2842 JNJ-40355003 Featured

JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor.

1394894-41-7
DCC2843 Jnj-40573663

Negaive control for JNJ-42396302

DCC2844 Jnj-40929837

Novel potent, orally active LTA4H inhibitor

1191044-42-4
DCC2845 Jnj-42396302

Novel inhibitor of PDE10A

1298030-18-8
DCC2846 Jnj-42491293

Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2)

1376334-37-0
DCC2847 Jnj-49153390

Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion

DCC2848 Jnj-53721590

Negative control for JNJ-54119936

DCC2849 Jnj-61432059

Novel TARP γ-8 Selective AMPAR Negative Modulator

2035814-50-5
DCC2850 Jnj-dgat1-a

Selective DGAT1 inhibitor

1092067-85-0
DCC2851 Jnj-dgat2-b

Selective DGAT2 inhibitor

DCC2852 Jns 1-40

Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth

DCC2853 Jp1201

Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner

DCC2854 Jp4-039

Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs)

1205492-16-5
DCC2855 Jr-220

Non-toxic anti-relapse agent, acamprosate

6933-71-7
DCC2856 Jra-003

Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC)

DCC2857 Jrc-ii-191

Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor

DCC2858 Js399-19

Novel specific inhibitor of Fusarium myosin I; Fungicide

39491-78-6
DCC2859 Jsf-2019

Novel antitubercular agent, inhibiting InhA and FAS-II pathway

DCC2860 Jsf-2513

Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway

DCC2861 Jsi287

Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway

DCC2862 Jte-151

Novel RORγ

1608139-41-8
DCC2863 Jte-607

Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha

188791-71-1
DCC2864 Jtk-853

Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase

954389-09-4
DCC2865 Jts-653

Novel orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist

942614-99-5
DCC2866 Jtt-552

Novel inhibitor of urate transporter 1 (URAT1)

888730-46-9
DCC2867 jtv-506

Novel K(ATP) channel opener

170148-29-5
DCC2868 Jtv-803 Mesylate

Specific inhibitor of factor Xa

247131-79-9
DCC2869 Julolidine Phenoxazone Azide

Novel live-cell peobe of voltage-dependent structural changes of voltage-gated Kv2.1 channels

DCC2870 jwb1-84-1 Trihydrochloride

Novel neuroprotective agent, improving cognitive performances in a transgenic mouse model of AD

491878-69-4
DCC2871 Jwg-115

Novel BET selective inhibitor, targeting BRD4

DCC2872 Jwh-007

Potent cannabinoid (CB) receptor agonist

155471-10-6
DCC2873 Jwu-a021

Novel potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro, also potently stimulating Ca(2+) influx through TRPA1 cation channels, being one of the most potent non-electrophilic TRPA-1 channel agonists

1403610-23-0
DCC2874 Jxl069

Novel potent mitochondrial pyruvate carrier (MPC) inhibitor to treat hair loss

DCC2875 Jy-1-106

Novel BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak

DCC2876 Jyl-1511

High-affinity partial agonist of the vanilloid receptor

623166-14-3
DCC2877 Jyl-273

Potent TRPV1 agonist

1391826-17-7
DCC2878 Jyl-79

Potent vanilloid receptor (VR1) agonist

289902-64-3
DCC2879 Jy-xhe-053

Selective modulator of GABAA receptors containing the α5 subunit

612526-36-0
DCC2880 Jz-4109

Novel β-Glucocerebrosidase modulator, promoting dimerization of β-glucocerebrosidase and revealing an allosteric binding site, stabilizing wild-type and N370S mutant GCase and increases GCase abundance in patient-derived fibroblast cells

DCC2881 Jz-5029

Novel irreversible β-Glucocerebrosidase modulator

DCC2882 jzad-iv-22

Inhibitor of all three monoamine transporters

1333245-01-4
DCC2883 Jzp-430

Potent, highly selective, and irreversible ABHD6 Inhibitor

1672691-74-5
DCC2884 K00135

Novel potent and selective inhibitor of PIM kinases

869650-21-5
DCC2885 K00518

Novel dual CLK1 and CLK3 inhibitor

DCC2886 K103 Hydrochloride

Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor

1071544-43-8
DCC2887 K-14585

Novel antagonist for proteinase-activated receptor 2 (PAR2)

880546-17-8
DCC2888 K4610422

Novel norditerpenoid inhibitor of testosterone-5α-reductase

DCC2889 K-8008

Novel inhibitor of the interaction of the N-terminally truncated RXR

2276730-51-7
DCC2890 K-8012

Novel inhibitor of the interaction of the N-terminally truncated RXR

1346513-17-4
DCC2891 Kaempulchraol P

Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression

DCC2892 Kaempulchraol Q

Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression

DCC2893 Kalb001

Novel mGlu4 ligand

DCC2894 Kar425

Novel antimalarial agent, providing protection to malaria-infected mice

1809050-49-4
DCC2895 Kasugamycin

Antibiotic, binding within the mRNA channel of the 30S subunit and inhibiting protein synthesis

6980-18-3
DCC2896 Kb130015

Novel activator of hERG1 potassium channels, blocking native and recombinant hERG1 channels at high voltages, but activating them at low voltages

147030-48-6
DCC2897 Kbh-a42

Novel histone deacetylase inhibitor

798543-50-7
DCC2898 Kbjk557

Novel Plk1 PBD inhibitor, showing a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells

DCC2899 Kb-nb165-09

Selective inhibitor of Protein_kinase_D1>protein kinase D (PKD); Inhibitor of cell adhesion and HIV; Inhibitor of herpes simplex virus type 1 replication

172832-10-9
DCC2900 Kbp-088

Novel highly potent dual amylin and calcitonin receptor agonist (DACRA), showing long-lasting improvement of food preference and body weight loss

DCC2901 Kb-r7785

Novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the in

168158-16-5
DCC2902 Kc-11404

LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor,and 5-lipoxygenase

148490-22-6
DCC2903 Kca075

Highly specific transglutaminase 2 (TG2) inhibitor

DCC2904 Kca-1490

Dual PDE3/4 inhibitor

909719-71-7
DCC2905 Kca2 Positive Modulator 2q

Novel potent and Subtype-Selective Positive Modulator of KCa2 Channels

DCC2906 Kcal01

Potent PDZ domain peptide inhibitor that rescues CFTR activity

DCC2907 Kdm4c-in-35

Novel selective KDM4C inhibitor

1841508-48-2
DCC2908 Kdm4-in-i

Novel KDM4 inhibitor

23705-85-3
DCC2909 Kdoam-20

Potent and selective KDM5 inhibitor

DCC2910 Kdoam-21

Potent and selective KDM5 inhibitor

DCC2911 Kemptide Acetate Salt

Phosphate acceptor peptide substrate for cAMP-dependent protein kinase

1629902-50-6
DCC2912 Kf15372

Potent and selective adenosine A1 antagonist with renal protective and diuretic activities

131080-42-7
DCC2913 Kfa1982

Novel and potent factor Xa inhibitor

409358-98-1
DCC2914 Kgchm07

Novel potent peptide dual agonist of opioid/neurokinin 1 receptor

DCC2915 Kh-carb13 Hydrochloride

Novel Pim-1 kinase Inhibitor, dose-dependent decreasing the viability of LS174T and HCT-116 cells

1353572-78-7
DCC2916 Khg21834

Inhibitor of Aβ-induced inflammation

940938-64-7
DCC2917 Khg26693

Novel anti-inflammatory and antioxidant agent, significantly decreasing blood glucose, triglycerides, and cholesterol and increased insulin

1497249-95-2
DCC2918 Ki23057

Novel FGFR2 inhibitor, enhancing the chemosensitivity of drug-resistant gastric cancer cell lines

516523-31-2
DCC2919 Kif18a Inhibitor 23

Novel KIF18A inhibitor, causing significant mitotic arrest in vivo, binding at the interface of KIF18A and tubulin

DCC2920 Ki-ms2-008

Novel Max-binding modulator, attenuating Myc-driven transcription and stabilizing the Max homodimer

DCC2921 kin100

Novel inducer of the ISG54 promoter, causing IRF-3 translocation

299952-11-7
DCC2922 Kir1.1-in-a

Novel potent and selective inhibitor of kir1.1 channels

DCC2923 Kist301072

Novel ROS1 kinase inhibitor

DCC2924 Kist301080

Novel ROS1 kinase inhibitor

DCC2925 Kjm429

Novel TRPV1 antagonist

401907-57-1
DCC2926 Kj-pyr-10

Novel specific inhibitor of MYC

DCC2927 Kkha-761

Potent D3 receptor antagonist with high 5-HT1A receptor affinity

DCC2928 Kl-1156

Novel NF-κB inhibitor and lipopolysaccharide (LPS)-induced nitric oxide production inhibitor

819868-62-7
DCC2929 Kld-12

Self-assembling peptide, forming a hydrogel matrix to support growth of cells in the presence of an ionic solution, enhancing chondrogenic differentiation of bone marrow stromal cells (BMSCs)

800379-47-9
DCC2930 Klebsazolicin

Novel inhibitor of 70S ribosome by obstructing the peptide exit tunnel

2257496-47-0
DCC2931 Klk6-in-32

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

DCC2932 Klk6-in-42

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

DCC2933 Kl-l9p

Novel antibiotic sensitizer, promoting the rearrangement of the bacterial membrane that enables hydrophobic antibiotics to permeate, strongly sensitizing Gram-negative bacteria to linezolid (Lzd), rifampicin (Rif), or clarithromycin (Clr)

DCC2934 Boc-phe-leu-glup(oph)

0

DCC2935 Km05382

CDK9 inhibitor, inhibiting transcription of GAPDH

882291-64-7
DCC2936 km10340

Selective S1P3 agonist

844635-76-3
DCC2937 Km-5-25

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

DCC2938 Km-5-66

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

DCC2939 kmi-1764

Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position

1469987-42-5
DCC2940 Kmn-010034

Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor

DCC2941 Kmn-80

Novel Potent and Selective EP4 Agonist

1628759-75-0
DCC2942 kms80013

Novel inhibitor of amyloid-

930284-65-4
DCC2943 Kms88009

Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder

1089681-42-4
DCC2944 Kmup-3

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

421556-16-3
DCC2945 Kmup-4

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

864873-81-4
DCC2946 Kongensin D

Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects

DCC2947 kp1212

Novel non-chain terminating nucleoside analog anti-HIV inhibitor

114522-16-6
DCC2948 Kpt-6604

Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer

DCC2949 Kpu-300

Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn.

1620692-60-5
DCC2950 Kr-12-a4

Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity

DCC2951 Kr-25210

Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus

DCC2952 Kr-31762

Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury

DCC2953 Kras(g12c)-in-1

Novel irreversible inhibitor of KRAS(G12C)

DCC2954 Kras4b-in-d14

Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells

924249-06-9
DCC2955 Kras4b-pdeδ Stabilizer C19

Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling

1049727-35-6
DCC2956 Krc-108

Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met

1146944-35-5
DCC2957 Krc-327

Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.

1350612-75-7
DCC2958 Krm-ii-08

Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c

DCC2959 Krn4884

Potassium channel opener

152802-84-1
DCC2960 Krn-8602 Hydrochloride

Topo II inhibitor, exhibiting cytotoxic effects against tumour cells

131722-57-1
DCC2961 Krp-109

Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes

1275996-50-3
DCC2962 Krp-199

Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo

221164-28-9
DCC2963 Krp-204

Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity

220475-76-3
DCC2964 Ks-133

Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders

DCC2965 Ksc-392-150

Novel inhibitor of the permeability transition pore (PTP)

DCC2966 kscm-1

Selective ligand of the sigma-1 receptor

1415247-17-4
DCC2967 Kscm-11

Ligand of the sigma receptor

1415247-16-3
DCC2968 kscm-5

Ligand of the sigma receptor

1415247-18-5
DCC2969 Ksk120

Novel inhibitor of transcriptional activity in Chlamydia trachomatis

1638100-63-6
DCC2970 Ksl-128114

Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma

DCC2971 Kspa-1

Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP

264207-32-1
DCC2972 Kt-182

Potent and selective inhibitor of ABHD6

1402612-62-7
DCC2973 Kt2-962

TXA2/prostaglandin endoperoxide receptor antagonist

129648-96-0
DCC2974 Kta-439

Thyroid hormone receptor β (TRβ) selective agonist

575503-70-7
DCC2975 Ku-2285

Hypoxic cell radiosensitizer

121077-11-0
DCC2976 Kufal194

Novel selective DYRK1A inhibitor

DCC2977 Kunb31

Novel potent and selective inhibitor of Hsp90β

2220263-80-7
DCC2978 Kurasoin B

Novel protein farnesyltransferase inhibitor

193696-42-3
DCC2979 kv1.5-in-iiii

Potent Kv1.5 inhibitor

1469902-72-4
DCC2980 Kv2.1/syntaxin-in-cpd5

Novel neuroprotectant, inhibiting Kv2.1-syntaxin molecular interaction

DCC2981 Kva-d-88

Novel Preferable Phosphodiesterase 4B (PDE4B) Inhibitor, Decreasing Cocaine-Mediated Reward Properties in Vivo

2410550-31-9
DCC2982 Ky1022

Ras destabilizer, targeting the Wnt/ß-catenin pathway and inhibiting development of metastatic colorectal cancer

1029721-36-5
DCC2983 Kya1797

Novel inhibitor of the Wnt/ß-catenin pathway, binding directly to the regulators of G-protein signaling domain of axin, initiating ß-catenin and Ras degradation through enhancement of the ß-catenin destruction complex activating GSK3ß, effectively suppres

851304-36-4
DCC2984 Kys05047

Selective T-type Ca(2+) channel blocker with anti-proliferative effects against various cancer cells

839672-57-0
DCC2985 L-161240

Potent inhibitor of LpxC and lipid A biosynthesis

183298-68-2
DCC2986 L-162782

Nonpeptide agonist of angiotensin AT1 receptor

169281-92-9
DCC2987 L17er4

Novel cell-permeable attenuated cationic amphiphilic lytic (ACAL) peptide, efficiently bring immunoglobulin G (IgG) and other functional proteins into cells

DCC2988 L2-4048

Novel Migration Inhibitory Factor (MIF) inhibitor, binding at the allosteric and tautomerase sites, blocking MIF's tautomerase CD74 receptor binding, and pro-inflammatory activities

DCC2989 L458-bpyne

Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species

1374647-07-0
DCC2990 L465046 (α-synuclein Amyloid Aggregation Inhibitor)

Novel inhibitor of α-synuclein amyloid aggregation for the treatment of Parkinson's disease

675171-18-3
DCC2991 L524-0366

Novel inhibitor of the TWEAK-Fn14 signaling cascade

951612-19-4
DCC2992 L61h46

Novel potent inhibitor of human pancreatic cancer cells

<Prev1...166167168169170...191Next>